Short communicationAntihypertensive effects of BQ-123, a selective endothelin ETA receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt

Add time:09/03/2019    Source:sciencedirect.com

We determined the antihypertensive effects of BQ-123 (cyclo(-d-Trp-d-Asp-l-Pro-d-Val-l-Leu-), sodium salt), a selective endothelin ETA receptor antagonist, in spontaneously hypertensive rats treated with deoxycorticosterone acetate-salt (DOCA-salt SHR). BQ-123 (1–30 mg/kg/h) decreased blood pressure in DOCA-salt SHR in a dose-dependent manner, although plasma immunoreactive endothelin-1 did not significantly increase and the maximal contractile response to endothelin-1 in the aorta significantly decreased as compared with values observed in age-matched SHR. These results suggest that endogenous endothelin-1 is involved in the maintenance of hypertension in DOCA-salt SHR, and that circulating endothelin-1 is not sufficient to reflect the physiological role of endothelin-1.

We also recommend Trading Suppliers and Manufacturers of BQ-123 SODIUM SALT (cas 136553-81-6). Pls Click Website Link as below: cas 136553-81-6 suppliers

Prev:Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721
Next:Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury)